Profitability Metrics

Gross Margin
36.61%
Operating Margin
14.57%
Net Margin
7.40%

Efficiency Metrics

Revenue per Expense Ratio
1.18
R&D as % of Revenue
1.40%

Earnings Quality

EBITDA Margin
16.76%
Income Tax Rate
30.00%
EPS
3.3800000000

Balance Sheet Analysis

Current Ratio
1.61
Cash Ratio
0.16
Working Capital
$377.64M
Debt to Equity
0.70
Debt to Assets
29.19%
Equity Ratio
41.98%

Cash Flow Analysis

Operating Cash Flow Ratio
11.91%
Free Cash Flow Ratio
10.17%
CapEx to Revenue
1.74%
Dividends Paid
$13.34M
Stock Buybacks
No buybacks
Total Shareholder Returns
$13.34M
Cash Position Change
41.62%

Key Takeaways (2023 FY)

  • Increased dividend payments by 119.73%
  • Increased R&D investment by 7.78%

Detailed Growth Metrics

Core Performance

Revenue
6.99%
Net Income
-8.25%
EPS
-9.38%
Operating Income
22.82%

Operational Efficiency

R&D Expenses
7.78%
SG&A Expenses
10.14%
Operating Cash Flow
54.18%
Free Cash Flow
62.14%

Balance Sheet Health

Assets
1.99%
Debt
-9.69%
Book Value per Share
18.32%
Inventory
-5.75%

Shareholder Returns

Dividends per Share
119.73%
Shares Outstanding
0.30%

Long Term Trends

3Y Revenue/Share
41.82%
5Y Revenue/Share
23.00%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%